Cargando…
571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed
BACKGROUND: HIV-infected African-Americans [AA] are more likely to experience virologic failure (VF) compared with other ethnic groups. Decreased access to healthcare has been postulated as a potential cause. Using data from the US Military Natural History Study (NHS), we examined the effects of rac...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253896/ http://dx.doi.org/10.1093/ofid/ofy210.579 |
_version_ | 1783373599387680768 |
---|---|
author | Ganesan, Anuradha Won, Seunghyun Joya, Christie Deiss, Robert Maves, Ryan Kronmann, Karl Lalani, Tahaniyat Schofield, Christina Whitman, Timothy J Okulicz, Jason Agan, Brian |
author_facet | Ganesan, Anuradha Won, Seunghyun Joya, Christie Deiss, Robert Maves, Ryan Kronmann, Karl Lalani, Tahaniyat Schofield, Christina Whitman, Timothy J Okulicz, Jason Agan, Brian |
author_sort | Ganesan, Anuradha |
collection | PubMed |
description | BACKGROUND: HIV-infected African-Americans [AA] are more likely to experience virologic failure (VF) compared with other ethnic groups. Decreased access to healthcare has been postulated as a potential cause. Using data from the US Military Natural History Study (NHS), we examined the effects of race on VF. The NHS is a longitudinal cohort comprised of Department of Defense (DoD) beneficiaries with unrestricted access to healthcare. METHODS: We included NHS participants who contributed follow-up after 2001. Demographic characteristics, antiretroviral therapy (ART) history, and serial viral loads (VL) were obtained from the database. Pharmacy records were used to calculate adherence. VF was defined as a VL of (3)200 copies/mL on two consecutive measurements or one VL of >1,000 c/mL. A Cox model with time-updated covariates was used to examine the association between race and VF. RESULTS: A total of 1,521 subjects contributed follow-up after 2001 (41% AA; 95% male). Median age, CD4 count and VL at ART initiation (AI) were 31.6 years [IQR 26–39], 367 cells/μl [IQR 271–489] and 4.6 log(10) copies/mL [IQR 4.0–5.0], respectively. Subjects were followed for a median of 4.8 years [IQR 2.7–7.9], and 13.2% (n = 201) met criteria for VF. Most subjects initiated ART with a non-nucleoside reverse transcriptase inhibitor (NNRTI) (64%), integrase strand transferase inhibitor (InSTI) (15%) or a boosted protease inhibitor (PI) (14%)-based regimen. Results of the adjusted Cox model are in the table below. CONCLUSION: In the NHS, in recent years, AA and Caucasians have similar responses to ART. NNRTI and InsTI use was protective, reinforcing that simpler medications with fewer adverse effects improve outcomes. Unrestricted access to care and modernization of ART should help narrow the disparities observed in virologic outcomes. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6253896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62538962018-11-28 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed Ganesan, Anuradha Won, Seunghyun Joya, Christie Deiss, Robert Maves, Ryan Kronmann, Karl Lalani, Tahaniyat Schofield, Christina Whitman, Timothy J Okulicz, Jason Agan, Brian Open Forum Infect Dis Abstracts BACKGROUND: HIV-infected African-Americans [AA] are more likely to experience virologic failure (VF) compared with other ethnic groups. Decreased access to healthcare has been postulated as a potential cause. Using data from the US Military Natural History Study (NHS), we examined the effects of race on VF. The NHS is a longitudinal cohort comprised of Department of Defense (DoD) beneficiaries with unrestricted access to healthcare. METHODS: We included NHS participants who contributed follow-up after 2001. Demographic characteristics, antiretroviral therapy (ART) history, and serial viral loads (VL) were obtained from the database. Pharmacy records were used to calculate adherence. VF was defined as a VL of (3)200 copies/mL on two consecutive measurements or one VL of >1,000 c/mL. A Cox model with time-updated covariates was used to examine the association between race and VF. RESULTS: A total of 1,521 subjects contributed follow-up after 2001 (41% AA; 95% male). Median age, CD4 count and VL at ART initiation (AI) were 31.6 years [IQR 26–39], 367 cells/μl [IQR 271–489] and 4.6 log(10) copies/mL [IQR 4.0–5.0], respectively. Subjects were followed for a median of 4.8 years [IQR 2.7–7.9], and 13.2% (n = 201) met criteria for VF. Most subjects initiated ART with a non-nucleoside reverse transcriptase inhibitor (NNRTI) (64%), integrase strand transferase inhibitor (InSTI) (15%) or a boosted protease inhibitor (PI) (14%)-based regimen. Results of the adjusted Cox model are in the table below. CONCLUSION: In the NHS, in recent years, AA and Caucasians have similar responses to ART. NNRTI and InsTI use was protective, reinforcing that simpler medications with fewer adverse effects improve outcomes. Unrestricted access to care and modernization of ART should help narrow the disparities observed in virologic outcomes. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253896/ http://dx.doi.org/10.1093/ofid/ofy210.579 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Ganesan, Anuradha Won, Seunghyun Joya, Christie Deiss, Robert Maves, Ryan Kronmann, Karl Lalani, Tahaniyat Schofield, Christina Whitman, Timothy J Okulicz, Jason Agan, Brian 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed |
title | 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed |
title_full | 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed |
title_fullStr | 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed |
title_full_unstemmed | 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed |
title_short | 571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed |
title_sort | 571. in a well-characterized cohort with universal access to care and medications racial disparities in hiv virologic outcomes are no longer observed |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253896/ http://dx.doi.org/10.1093/ofid/ofy210.579 |
work_keys_str_mv | AT ganesananuradha 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved AT wonseunghyun 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved AT joyachristie 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved AT deissrobert 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved AT mavesryan 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved AT kronmannkarl 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved AT lalanitahaniyat 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved AT schofieldchristina 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved AT whitmantimothyj 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved AT okuliczjason 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved AT aganbrian 571inawellcharacterizedcohortwithuniversalaccesstocareandmedicationsracialdisparitiesinhivvirologicoutcomesarenolongerobserved |